RightFit
RecruitingPhase 2

Sit Less, Interact and Move More (SLIMM) 2 Study

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
20 Years and older
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study is for people with long-term kidney disease. It tests whether guided muscle-strength exercises and semaglutide, a medicine for diabetes and weight loss, help people stick with a program to sit less and move more.

* Prolonged sitting (sedentary behavior) is a risk factor for decreased kidney function, obesity, diabetes and mortality. Prolonged sitting is associated with decreased kidney function and increased risk of diabetes, heart disease and death. * In a previous pilot study funded by NIH, it was shown that a Sit Less, Interact and Move More (SLIMM) intervention targeting sedentary behavior in people with kidney disease was able to decrease prolonged sitting but that effect was not sustained. * Therefore, the researchers are currently conducting a follow-up study named Sit Less, Interact and Move More (SLIMM) 2. * This NIH funded study is conducted at the University of Utah and Stanford University. * The purpose of this study is to see if guided resistance training (to improve muscle strength) and semaglutide (FDA approved diabetes and weight loss medication that might also improve physical function) can boost adherence to the SLIMM Intervention and reduce sedentary behavior.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Have an eGFR of 20 to less than 60, a blood test estimate of how well your kidneys filter waste.
  • Be able to do muscle-strength exercises.
  • Have access to a compatible smartphone, tablet, or computer with internet or mobile service.

Who can't join

  • Have type 1 diabetes.
  • Have had slow stomach emptying, stopped movement in the intestines, or weight-loss surgery.
  • Sit for 25 minutes per hour or less at the start, as measured by a movement tracker.
  • Have health risks that may make semaglutide unsafe, such as past swelling of the pancreas or a personal or family history of MEN2 or medullary thyroid cancer. MEN2 is a condition that causes tumors in hormone-making glands.
  • Have used a GLP-1 medicine, the same type of drug as semaglutide, within 30 days before screening.
  • Expect to start dialysis, a treatment that filters blood, or get a kidney transplant within 6 months.
  • Have had a hospital stay or major medical procedure within the past 60 days.
  • Are pregnant or in prison.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Glomerular Filtration Rate (eGFR) 20 to \<60 mL/min/1.73m\^2 * Able to perform resistance training * Access to compatible "smartphone" or device (i.e., Android, Kindle or Apple with internet connectivity or mobile network), desktop or laptop Exclusion Criteria: * Type 1 Diabetes * History of gastroparesis or paralytic ileus * At baseline, if sedentary time is 25 min/hr or less, measured by accelerometer * Potential contraindications to semaglutide such as a history of pancreatitis, and a family or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma. * Previous bariatric surgery * Medical condition likely to limit survival to less than 1 year * Anticipated start of dialysis or kidney transplantation within 6 months * Any factors judged by the investigator or study team to likely limit adherence to interventions * Vulnerable populations- pregnant or incarcerated * Enrolled in interventional trials using drugs or devices * Not able to undergo informed consent * Recent hospitalizations or major interventional procedures done within the past 60 days * Known or suspected hypersensitivity to tegaderm * Use of any GLP-1 receptor agonist within 30 days prior to screening * Presently classified as being in New York Heart Association (NYHA) Class IV Heart Failure * Daytime use of supplemental oxygen (i.e., prescribed a stationary or portable oxygen system) * Presence of metastatic cancer * Current use of mobility aid(s) * Living in the same household of a participant already enrolled in the study

Study sites (2)

CA

UT